Esperion Therapeutics (ESPR) Long-Term Deferred Tax (2016 - 2017)
Esperion Therapeutics (ESPR) reported Long-Term Deferred Tax of $99.8 million for Q4 2017, up 32.54% on a YoY basis from $75.3 million in Q4 2016, and up 32.54% quarter-over-quarter from $75.3 million in Q4 2016.
Esperion Therapeutics (ESPR) Long-Term Deferred Tax (2016 - 2017) Analysis & Trends
Esperion Therapeutics has reported Long-Term Deferred Tax for 2 years, with the latest figure at $99.8 million in Q4 2017.
- For the quarter ending Q4 2017, Long-Term Deferred Tax rose 32.54% year-over-year to $99.8 million; the trailing twelve-month figure through Dec 2017 stood at $99.8 million (up 32.54% YoY), and the FY2017 full-year result was $99.8 million, up 32.54% from the prior year.
- Long-Term Deferred Tax for Q4 2017 stood at $99.8 million, up from $75.3 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $99.8 million in Q4 2017, with the low at $75.3 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Esperion Therapeutics | 49.69 Mn | -118.16 Mn | 45.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 99.80 Mn |
| Dec 31, 2016 | 75.30 Mn |